PMID: 9421824Jan 9, 1998Paper

Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications

Progress in Neuro-psychopharmacology & Biological Psychiatry
R Miller

Abstract

1. From a review of published literature it is concluded that the minimum dose of a neuroleptic drug (NLD) required to alleviate psychosis is very similar to that producing minimal parkinsonian side effects (PSE). This conclusion is reached both from group comparisons and individual comparisons of dose/response relations (DRR) for the two effects. 2. A lower dose of NLD is usually sufficient to prevent relapse in well stabilized patients than is needed to check an active psychotic state. 3. Anticholinergic agents used to reduce side effects of typical NLD can retard the therapeutic process during neuroleptic treatment of acute psychosis. Although it is not fully established that this is a central interaction, it is consistent with the idea that minimal side effects are a necessary condition for therapeutic effectiveness with typical antipsychotic drugs. 4. In relapse-free maintenance of psychosis-prone patients, tolerance occurs to PSE. Thus few patients need experience prolonged side effects during maintenance treatment with neuroleptics. 5. The evidence reviewed is discussed with respect to a previous hypothesis of the supposedly "indirect" action of typical neuroleptic drugs in therapy for psychosis. The evidence is consiste...Continue Reading

References

Jan 1, 1978·Clinical Pharmacokinetics·T B Cooper
Jul 6, 1978·Psychopharmacology·G M SimpsonB Zoubok
Jan 1, 1978·Schizophrenia Bulletin·T ZiembaJ M Davis
Jan 1, 1976·Schizophrenia Bulletin·H Y Meltzer, S M Stahl
May 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·S R MarderJ Mintz
Jan 1, 1989·Pharmacology, Biochemistry, and Behavior·W J Freed
Jan 1, 1989·Neuropsychobiology·O A SolanoJ Ananth
Jun 1, 1989·The Australian and New Zealand Journal of Psychiatry·R Miller
Dec 1, 1985·Pharmacology, Biochemistry, and Behavior·W R Klemm
Jun 1, 1986·The Australian and New Zealand Journal of Psychiatry·G Caradoc-DaviesP E Mullen
Dec 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·J S BamrahS D Soni
Oct 1, 1988·Journal of Clinical Psychopharmacology·F Miller, J H Tanenbaum
Jun 1, 1986·Journal of Clinical Psychopharmacology·J P McEvoyR Farr
Jan 1, 1970·Psychopharmacologia·M L ClarkJ P Costiloe
Apr 8, 1974·Psychopharmacologia·H WijsenbeekS C Goldberg
Jul 1, 1973·The Journal of Nervous and Mental Disease·M M Singh, J M Smith
Jan 1, 1966·Psychopharmacologia·T E HanlonA A Kurland
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·J W Angus, G M Simpson
Jan 1, 1982·Psychopharmacology·T NishikawaY Uchida
Aug 1, 1983·Psychological Medicine·E C JohnstoneS J Gamble
Dec 1, 1984·Psychiatry Research·S W TangP Seeman
Jan 1, 1981·Psychopharmacology·M W DyskenJ M Davis

❮ Previous
Next ❯

Citations

Feb 20, 2002·Journal of Advanced Nursing·Sue JordanAlan Sykes
Nov 9, 2004·International nursing review·S JordanD Pointon
Aug 29, 2013·The Cochrane Database of Systematic Reviews·Lorna DonnellyClive E Adams
Jul 10, 2014·The Cochrane Database of Systematic Reviews·Magdolna TardyStefan Leucht
Nov 7, 2019·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Paulina Trombik, Katarzyna Cieślik-Boczula

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here